Description

BPC-157 Technical Data Sheet

Compound Identification

Systematic Name: Body Protection Compound-157
Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Molecular Formula: C62H98N16O22
Molecular Weight: 1419.53 g/mol
CAS Number: 137525-51-0
Peptide Type: Pentadecapeptide (15 amino acids)

Chemical Properties

Appearance: White to off-white lyophilized powder
Solubility: Soluble in water, physiological saline
Stability: Stable as lyophilized powder at -20°C for 24 months
pH Stability Range: 5.0-7.0
Storage Requirements: Store lyophilized material at -20°C, protected from light. Once reconstituted, store at 2-8°C and use within 14 days.

Origin and Background

BPC-157 is a synthetic peptide derived from a protective peptide found in gastric juice. The compound was first isolated and characterized by researchers at the University of Zagreb in the 1990s. It represents a partial sequence of body protection compound (BPC) and has been investigated in various animal models since its discovery.

Proposed Mechanisms (Based on Preclinical Research)

Research in animal models has explored several potential mechanisms:

• Angiogenesis modulation: Studies suggest interaction with vascular endothelial growth factor (VEGF) pathways in rodent models
• Nitric oxide pathways: Preclinical data indicates potential effects on NO-mediated signaling
• Growth factor modulation: Animal studies have examined interactions with various growth factor systems
• GABAergic system interaction: Limited research suggests potential effects on GABA neurotransmission in rodent models

Note: Mechanisms are primarily established through animal research. Human mechanistic data remains limited.

Research Applications in Animal Models

Gastrointestinal Research

Published studies have examined BPC-157 in rodent models of gastrointestinal injury, including ulcer models and inflammatory bowel conditions. Research protocols typically employed doses ranging from 10 μg/kg to 10 mg/kg via intraperitoneal or intragastric administration.

Musculoskeletal Research

Animal studies have investigated effects on tendon healing, ligament injury, and muscle damage models. Common research protocols used subcutaneous or intraperitoneal injection routes in rat models.

Cardiovascular Research

Preclinical studies have examined effects in models of vascular injury and ischemia-reperfusion. Research has primarily been conducted in rat models.

Neuropharmacological Research

Limited studies have explored effects in rodent models of brain injury and neurotransmitter system modulation.

In Vitro Research Parameters

Cell culture studies have examined concentrations ranging from 0.1 μg/mL to 100 μg/mL in various cell lines including:

• Fibroblast cultures (tendon healing models)
• Endothelial cell lines (angiogenesis studies)
• Gastrointestinal epithelial cells

Research Limitations and Considerations

Species Specificity: Vast majority of research conducted in rodent models; extrapolation to other species requires validation.

Route of Administration: Most published research utilizes injection routes (IP, SC); oral bioavailability data is limited and conflicting.

Dosing Variability: Published studies show wide dose ranges with limited dose-response characterization.

Replication Status: Many findings require independent replication by research groups outside the original discovery institution.

Human Data: No published peer-reviewed clinical trials in humans as of current literature review.

Regulatory Status: Not approved for human or veterinary use by FDA, EMA, or comparable regulatory agencies.

Reconstitution Protocol for Laboratory Use

1. Add appropriate volume of sterile bacteriostatic water or saline to lyophilized powder
2. Allow to stand at room temperature for 2-3 minutes
3. Gently swirl (do not vortex or shake vigorously)
4. Visually inspect for complete dissolution
5. Use immediately or store at 2-8°C for maximum 14 days

Quality Control Specifications

Purity: ≥95% by HPLC analysis
Peptide Content: ≥80% by amino acid analysis
Endotoxin Level: <1.0 EU/mg
Water Content: <5% (Karl Fischer)
Sterility: Passes USP <71> sterility test

Safety Considerations for Laboratory Handling

• Use appropriate PPE (gloves, lab coat, safety glasses)
• Handle in well-ventilated area or biosafety cabinet
• Avoid skin contact and inhalation
• Follow institutional chemical safety protocols
• Dispose of according to local regulations for peptide/protein waste

Selected References from Primary Literature

1. Sikiric, P., et al. (1993). A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology Paris, 87(5), 313-327.
2. Sikiric, P., et al. (2014). Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 20(7), 1126-1135.
3. Chang, C.H., et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774-780.
4. Kang, E.A., et al. (2018). Essential role of endothelial nitric oxide synthase in BPC157-mediated protection against ethanol-induced gastric ulcers in rats. Journal of Physiology and Pharmacology, 69(1).

Research Use Statement

This compound is intended solely for in vitro research and animal studies conducted under appropriate institutional oversight (IACUC approval where applicable). Not intended for human or veterinary therapeutic use. Researchers are responsible for compliance with all applicable regulations governing research chemical procurement and use.